Loading institutional data...
Loading institutional data...
Held by 167 of 5,944 reporting institutions (90th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $3.40 today, the market must believe free cash flow compounds -3.5%/yr for a decade (off $161M normalized FCF).
The market's -3.5% is more conservative than its 7-yr track record.
2-stage DCF · 0.36B shares · net debt $226M
mean 25.4% · volatility σ 38% · implied rate exceeded in 4/7 yrs
Central path = implied -3.5%/yr growth; shaded band = ±1σ (38%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $216M buybacks = $216M returned on $164M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Modest payoff on reinvested capital. Current ROIC on all capital: 3%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $262M covers the $5M due within a year 52.4× over. Scheduled principal only (excludes interest & revolver draws). As of 2024-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~8.7% on $488M of debt.
Cash of $262M fully covers short-term debt of $5M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $796.9M 100.0% | $792.3M 100.0% | $750.3M 100.0% | $766.6M 100.0% | $745.4M 100.0% | $550.7M 100.0% | $388.2M 100.0% | $249.5M 100.0% |
| Research & Development | $121.0M 15.2% | $123.7M 15.6% | $135.8M 18.1% | $143.1M 18.7% | $125.9M 16.9% | $61.8M 11.2% | $29.3M 7.5% | $43.9M 17.6% |
| Selling, General & Admin | $114.0M 14.3% | $117.9M 14.9% | $125.5M 16.7% | $144.8M 18.9% | $154.7M 20.8% | $461.5M 83.8% | $14.7M 3.8% | $8.4M 3.4% |
| Total Operating Expenses | $709.4M 89.0% | $726.5M 91.7% | $777.3M 103.6% | $764.8M 99.8% | $732.0M 98.2% | $826.4M 150.1% | $248.5M 64.0% | $172.3M 69.0% |
| Operating Income | $87.5M 11.0% | $65.8M 8.3% | -$27.0M -3.6% | $1.7M 0.2% | $13.4M 1.8% | -$275.7M -50.1% | $139.7M 36.0% | $77.3M 31.0% |
| Interest Expense | $42.6M 5.3% | $52.9M 6.7% | $56.7M 7.6% | $34.2M 4.5% | $23.6M 3.2% | $27.9M 5.1% | $49.6M 12.8% | $22.2M 8.9% |
| Interest & Investment Income | $10.9M 1.4% | $23.3M 2.9% | $32.2M 4.3% | $9.3M 1.2% | $59K 0.0% | $160K 0.0% | $715K 0.2% | $154K 0.1% |
| Other Income (Expense), net | -$31.0M -3.9% | -$34.4M -4.3% | -$28.6M -3.8% | -$25.0M -3.3% | -$23.6M -3.2% | -$27.7M -5.0% | -$56.7M -14.6% | -$24.9M -10.0% |
| Pretax Income | $56.5M 7.1% | $31.5M 4.0% | -$55.6M -7.4% | -$23.2M -3.0% | -$10.2M -1.4% | -$303.4M -55.1% | $83.0M 21.4% | $52.3M 21.0% |
| Income Tax Expense | $26.1M 3.3% | $15.1M 1.9% | -$46.7M -6.2% | $9.6M 1.3% | $15.1M 2.0% | -$9.8M -1.8% | $16.9M 4.4% | $8.6M 3.4% |
| Net Income | $30.4M 3.8% | $16.4M 2.1% | -$8.9M -1.2% | -$32.8M -4.3% | -$25.3M -3.4% | -$293.6M -53.3% | $66.0M 17.0% | $43.8M 17.6% |
| Per Share | ||||||||
| EPS (Basic) | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 | $0.19 | $0.12 |
| EPS (Diluted) | $0.09 | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 | $0.18 | $0.12 |
| Weighted Avg Shares (Basic) | 356.3M | 385.7M | 410.3M | 412.9M | 410.0M | 274.7M | 226.6M | 111.8M |
| Weighted Avg Shares (Diluted) | 357.0M | 392.2M | 410.3M | 412.9M | 410.0M | 274.7M | 231.2M | 118.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
Where each multiple sits in its own 6-yr range · 20th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 6-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 57.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| R&D | 17.6 | 7.5 | 11.2 | 16.9 | 18.7 | 18.1 | 15.6 | 15.2 |
| SG&A | 3.4 | 3.8 | 83.8 | 20.8 | 18.9 | 16.7 | 14.9 | 14.3 |
| Operating Income | 31.0 | 36.0 | -50.1 | 1.8 | 0.2 | -3.6 | 8.3 | 11.0 |
| Income Tax | 3.4 | 4.4 | -1.8 | 2.0 | 1.3 | -6.2 | 1.9 | 3.3 |
| Net Income | 17.6 | 17.0 | -53.3 | -3.4 | -4.3 | -1.2 | 2.1 | 3.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on GDRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| GDRX | $1.2B | 37.8× | 15.7× | 1.5× | 0.6% | — | 3.8% | 4.9% | 2.8% | 5.3× | 167 |
Peers = companies sharing GDRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.